SCHEMBL434233

SCHEMBL434233

O=C(N[C@H](C(=O)O)c1ccccc1)OCc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.77
CTSL P07711 1/20 0.67
CTSS P25774 1/20 0.67
CTRB1 P17538 2/20 0.56
ALDH1A1 P00352 3/20 0.56
CYP1A2 P05177 2/20 0.56
OPRK1 P41145 2/20 0.54
PPARG P37231 1/20 0.53
CYP2C9 P11712 4/20 0.52
CYP3A4 P08684 4/20 0.52
CYP2C19 P33261 3/20 0.52
TSHR P16473 3/20 0.52
POLB P06746 1/20 0.52
CASP1 P29466 1/20 0.52
CYP2D6 P10635 1/20 0.52
LMNA P02545 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3255533 1.00 ATM (0.77) ATMCTSLCTSSCTRB1ALDH1A1
SCHEMBL1362502 1.00 ATM (0.77) ATMCTSLCTSSCTRB1ALDH1A1
SCHEMBL7719287 1.00 ATM (0.77) ATMCTSLCTSSCTRB1ALDH1A1
SCHEMBL5742255 0.92 ATM (0.67) ATMCTSLCTSSCTRB1ALDH1A1
SCHEMBL17765000 0.92 ATM (0.67) ATMCTSLCTSSCTRB1ALDH1A1
SCHEMBL5742261 0.92 ATM (0.67) ATMCTSLCTSSCTRB1ALDH1A1
SCHEMBL11205232 0.90 ATM (0.64) ATMCTSLCTSSCTRB1LMNA
SCHEMBL28224944 0.90 ATM (0.64) ATMCTSLCTSSCTRB1ALDH1A1
SCHEMBL28224943 0.90 ATM (0.64) ATMCTSLCTSSCTRB1ALDH1A1
SCHEMBL6736883 0.89 ATM (0.70) ATMCTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059171-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-02-20 US disclosed
EP-4444711-A1 ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-10-16 EP disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 CN disclosed
US-20230279553-A1 Method for Manufacturing Conductive Pattern-Provided Structure ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-09-07 US disclosed
EP-4234758-A1 METHOD FOR MANUFACTURING CONDUCTIVE PATTERN-PROVIDED STRUCTURE Asahi Kasei Kabushiki Kaisha (JP) 2023-08-30 EP disclosed
WO-2023104882-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-06-15 WO disclosed
WO-2023078410-A1 COMPOUND HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF 上海美志医药科技有限公司 2023-05-11 WO disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 WO disclosed
EP-1060178-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER INC. (US) 2000-12-20 EP disclosed
EP-0998488-A1 POLYOL-AMINO ACID COMPOUNDS HAVING ANTI-HELICOBACTER PYLORI ACTIVITY Takeda Chemical Industries, Ltd. (JP) 2000-05-10 EP disclosed
WO-1999045006-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER INC. (US) 1999-09-10 WO disclosed
WO-1999002549-A1 POLYOL-AMINO ACID COMPOUNDS HAVING ANTI-HELICOBACTER PYLORI ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-01-21 WO disclosed
EP-0768303-A1 OPTICALLY ACTIVE QUINOLINECARBOXYLIC ACID DERIVATIVE AND PROCESS FOR PRODUCING THE SAME NIPPON SHINYAKU COMPANY, LIMITED (JP) 1997-04-16 EP disclosed
WO-1996027370-A1 FREE RADICAL SCAVENGER MOLECULES BRITISH TECHNOLOGY GROUP LIMITED (GB) 1996-09-12 WO disclosed
EP-0069894-B1 OPTICALLY ACTIVE DIPEPTIDES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1985-04-10 EP disclosed
US-4505854-A Optically active dipeptides and the use thereof as tissue dissolving and histolytic agent in human beings NATTERMANN & CIE GMBH (DE) 1985-03-19 US disclosed
EP-0074837-A1 4-Substituted pyridine catalysts REILLY TAR & CHEMICAL CORPORATION (US) 1983-03-23 EP disclosed
EP-0069894-A1 Optically active dipeptides, pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions containing them A. Nattermann & Cie. GmbH (DE) 1983-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059171-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, ACE, EIF2AK2 ATM 4706/4885CTSL 100/4885CTSS 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.